Extract

This is a phase II study evaluating the safety, tolerability and efficacy of BKM120 in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) or follicular lymphoma (FL).

Inclusion criteria

• Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma

Country

• Belgium
• France
• Germany
• Italy
• Korea, Republic of
• Spain
• Turkey
• United States

Links

• ictrp
• nct